In 2025, the FDA made significant strides in dermatology by expanding the indications for several established medications. Notable among these are Dupixent, Opzelura, and Zoryve, which received approvals for new applications in managing various dermatological conditions. This expansion highlights the evolving landscape of dermatological treatments, offering new hope for patients with chronic skin diseases.
Dupixent’s Expanded Applications
Dupixent, known generically as dupilumab, received two additional indications in 2025, bringing its total FDA-approved uses to eight. This versatile medication, already established in treating atopic dermatitis and asthma, has now been approved for bullous pemphigoid and chronic spontaneous urticaria.
Bullous pemphigoid is an autoimmune condition that primarily affects older adults, characterized by severe itching and blister formation. Chronic spontaneous urticaria, on the other hand, leads to persistent hives and is often challenging to manage with conventional antihistamines. The expanded indications for Dupixent provide targeted treatment options for these difficult-to-treat conditions, potentially improving the quality of life for many patients.
Zoryve’s Pediatric Approvals
Zoryve (roflumilast) also saw significant advancements. In October 2025, the FDA approved Zoryve cream 0.05% for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years. Earlier in the year, Zoryve foam 0.3% was cleared for use in treating plaque psoriasis on the scalp and body in individuals aged 12 and older.
This approval was particularly noteworthy as it extends treatment options to very young patients, addressing a critical gap in pediatric dermatology. The foam formulation’s unique delivery system allows for targeted application, making it easier to treat sensitive areas, such as the scalp, effectively.
Opzelura: A New Option for Young Patients
Opzelura (ruxolitinib) also expanded its reach in October 2025, becoming the first topical Janus kinase (JAK) inhibitor approved for use in children aged 2 to 11 years with mild to moderate atopic dermatitis. This approval fills a significant need in pediatric dermatology by providing a rapid, steroid-sparing treatment option.
A phase 3 clinical study demonstrated that children treated with Opzelura achieved significantly improved results compared to those receiving a placebo. This swift action in reducing itchiness and flare-ups helps manage symptoms without resorting to systemic therapies or prolonged steroid use, which can have adverse effects.
Libtayo for High-Risk Skin Cancer
Another significant development was the FDA’s approval of Libtayo (cemiplimab) in October 2025 for patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence post-surgery and radiation. As a PD-1 inhibitor, Libtayo enhances the immune response against cancer cells, offering new hope for patients with this often-overlooked skin cancer.
Previously, treatment options for high-risk CSCC were limited, making this approval a crucial advancement. It enables oncologists to better manage patients who are at a greater risk of recurrence, potentially improving their long-term outcomes.
Vyjuvek: Gene Therapy Breakthrough
In September 2025, Vyjuvek (beremagene geperpavec) received expanded approval for dystrophic epidermolysis bullosa (DEB) patients from birth. This gene therapy utilizes a herpes-simplex virus vector to deliver copies of the COL7A1 gene directly to wounds.
The updated label also simplified at-home application, empowering caregivers to manage treatment more effectively. Given the rare and devastating nature of DEB, this advancement represents a significant leap forward in patient care, facilitating easier integration of treatment into daily routines.
The Future of Dermatological Treatments
These recent FDA approvals signal a transformative period in dermatological care, providing patients with innovative options for managing chronic skin conditions. Each new indication not only broadens treatment horizons but also emphasizes the importance of addressing the unique needs of pediatric and high-risk populations.
As the field continues to evolve, ongoing research and development will undoubtedly yield further breakthroughs, enhancing patient outcomes and quality of life.
Key Takeaways
- Dupixent now treats bullous pemphigoid and chronic spontaneous urticaria, expanding its uses to eight conditions.
- Zoryve’s new approvals include a cream for young children with atopic dermatitis and a foam for plaque psoriasis in adolescents and adults.
-
Opzelura is now a viable option for children aged 2 to 11 with atopic dermatitis, offering rapid relief without systemic steroids.
-
Libtayo provides a new treatment avenue for high-risk cutaneous squamous cell carcinoma patients.
-
Vyjuvek’s expanded label allows for gene therapy application from birth, enhancing patient autonomy in managing dystrophic epidermolysis bullosa.
In conclusion, the advancements made in 2025 reflect a commitment to improving dermatological care through innovative therapies. These medications not only address pressing health needs but also pave the way for future developments in skin disease management.
